• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Pulm Med . Elevated glucose level leads to rapid COVID-19 progression and high fatality

tetano

Editor, Senior Moderator
BMC Pulm Med


. 2021 Feb 24;21(1):64.
doi: 10.1186/s12890-021-01413-w.
Elevated glucose level leads to rapid COVID-19 progression and high fatality


Wenjun Wang[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Mingwang Shen[SUP] #[/SUP][SUP] 4 [/SUP], Yusha Tao[SUP] 4 [/SUP], Christopher K Fairley[SUP] 4 5 [/SUP], Qin Zhong[SUP] 1 2 3 [/SUP], Zongren Li[SUP] 1 2 3 [/SUP], Hui Chen[SUP] 6 7 [/SUP], Jason J Ong[SUP] 4 5 [/SUP], Dawei Zhang[SUP] 8 [/SUP], Kai Zhang[SUP] 1 [/SUP], Ning Xing[SUP] 9 [/SUP], Huayuan Guo[SUP] 1 [/SUP], Enqiang Qin[SUP] 8 [/SUP], Xizhou Guan[SUP] 10 [/SUP], Feifei Yang[SUP] 1 [/SUP], Sibing Zhang[SUP] 6 11 [/SUP], Lei Zhang[SUP] 12 13 14 [/SUP], Kunlun He[SUP] 15 16 17 [/SUP]



Affiliations

Abstract

Objectives: We aimed to identify high-risk factors for disease progression and fatality for coronavirus disease 2019 (COVID-19) patients.
Methods: We enrolled 2433 COVID-19 patients and used LASSO regression and multivariable cause-specific Cox proportional hazard models to identify the risk factors for disease progression and fatality.
Results: The median time for progression from mild-to-moderate, moderate-to-severe, severe-to-critical, and critical-to-death were 3.0 (interquartile range: 1.8-5.5), 3.0 (1.0-7.0), 3.0 (1.0-8.0), and 6.5 (4.0-16.3) days, respectively. Among 1,758 mild or moderate patients at admission, 474 (27.0%) progressed to a severe or critical stage. Age above 60 years, elevated levels of blood glucose, respiratory rate, fever, chest tightness, c-reaction protein, lactate dehydrogenase, direct bilirubin, and low albumin and lymphocyte count were significant risk factors for progression. Of 675 severe or critical patients at admission, 41 (6.1%) died. Age above 74 years, elevated levels of blood glucose, fibrinogen and creatine kinase-MB, and low plateleta count were significant risk factors for fatality. Patients with elevated blood glucose level were 58% more likely to progress and 3.22 times more likely to die of COVID-19.
Conclusions: Older age, elevated glucose level, and clinical indicators related to systemic inflammatory responses and multiple organ failures, predict both the disease progression and the fatality of COVID-19 patients.

Keywords: COVID-19; Fatality; Progression; Risk factors.
 
Back
Top Bottom